TABLE 2.
Quantitation of immunolabeling on IMVs and intracellular cores with antibodies to VV core proteins and to DNA on cryosections
| Treatment | Time of infection (min)a | Labeling (avg ± SD)b
|
||||
|---|---|---|---|---|---|---|
| Anticorec | p39 | p11 | p25 | Anti-DNA | ||
| −ActD | Cores | |||||
| 60 | 13 ± 5 | 12 ± 3 | 0 | 5 ± 2 | 14 ± 8 | |
| 120 | 13 ± 5 | 8 ± 3 | 0 | 5 ± 3 | 4 ± 4 | |
| 180 | 5 ± 3 | 5 ± 3 | 0 | 1 ± 1 | 1 ± 1 | |
| IMV | 18 ± 6 | 12 ± 4 | 12 ± 3 | 6 ± 2 | 9 ± 3 | |
| +ActD | Cores | |||||
| 60 | 16 ± 5 | 10 ± 3 | 0 | 7 ± 2 | 21 ± 6 | |
| 120 | 12 ± 4 | 8 ± 3 | 0 | 6 ± 2 | 17 ± 7 | |
| 180 | 16 ± 5 | 9 ± 4 | 0 | 4 ± 3 | 18 ± 6 | |
| IMV | 19 ± 6 | 10 ± 3 | 9 ± 3 | 5 ± 3 | 11 ± 5 | |
a
Labeling on cryosections from cells infected in the absence (−ActD) or presence (+ActD) of actD.
b
Quantitation of labeling with antibodies to core proteins on intracellular cores accumulated for the indicated times of infection and on extracellular IMVs at 60 min of infection.
c
Average amount of labeling on 20 intracellular cores or on IMVs.